Sihuan Pharmaceutical Holdings Group (SZSC:460) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

460 주식 개요

투자 지주 회사인 시환 제약 홀딩스 그룹은 중화인민공화국에서 제약 및 의료 미용 제품의 연구 개발, 제조, 마케팅 및 판매에 종사하고 있습니다.

460 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	2/6

보상

지난 5년 동안 수입이 매년 13% 증가했습니다.

위험 분석

7.74% 의 배당금은 수익이나 잉여현금흐름으로 잘 충당되지 않습니다.

Sihuan Pharmaceutical Holdings Group Ltd. 경쟁사

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$6.4b

Beijing Tong Ren Tang Chinese Medicine

SEHK:3613

HK$7.2b

Consun Pharmaceutical Group

SEHK:1681

HK$5.6b

Tong Ren Tang Technologies

SEHK:1666

HK$6.6b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Sihuan Pharmaceutical Holdings Group
과거 주가
현재 주가	HK$0.58
52주 최고치	HK$0.71
52주 최저치	HK$0.49
베타	0.60
11개월 변경	9.43%
3개월 변경 사항	11.54%
1년 변경 사항	-4.92%
33년 변화	-65.06%
5년 변화	-45.79%
IPO 이후 변화	-72.38%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	460	HK Pharmaceuticals	HK 마켓
7D	7.4%	6.1%	9.8%
1Y	-4.9%	13.7%	12.9%

수익률 대 산업: 460 지난 1년 동안 -3.4 %를 반환한 Hong Kong Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: 460 지난 1년 동안 2.1 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 460's price volatile compared to industry and market?
460 volatility
460 Average Weekly Movement	4.5%
Pharmaceuticals Industry Average Movement	4.6%
Market Average Movement	6.6%
10% most volatile stocks in HK Market	13.6%
10% least volatile stocks in HK Market	3.5%

안정적인 주가: 460 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: 460 의 주간 변동성( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2001	2,648	Weicheng Guo	www.sihuanpharm.com

투자 지주 회사인 시환 제약 홀딩스 그룹은 중화인민공화국에서 제약 및 의료 미용 제품의 연구 개발, 제조, 마케팅 및 판매에 종사하고 있습니다. 이 회사는 세 가지 부문을 통해 운영됩니다: 메디컬 에스테틱 제품, 혁신 의약품 및 기타 의약품, 일반 의약품입니다. 이 회사는 필링, 성형, 지지, 보충, 광전자 장치, 신체 조각, 피부 관리 및 기타 비침습적 또는 최소 침습적 의료 미용 종합 솔루션을 제공합니다.

Sihuan Pharmaceutical Holdings Group Ltd. 기본 사항 요약

Sihuan Pharmaceutical Holdings Group 의 수익과 매출은 시가총액과 어떻게 비교하나요?
460 기본 통계
시가총액	HK$5.41b
수익(TTM)	-HK$41.91m
수익(TTM)	HK$1.95b

2.8x

P/S 비율

-129.0x

P/E 비율

460 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
460 손익 계산서(TTM)
수익	CN¥1.75b
수익 비용	CN¥598.10m
총 이익	CN¥1.16b
기타 비용	CN¥1.19b
수익	-CN¥37.80m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.0041
총 마진	65.91%
순이익 마진	-2.15%
부채/자본 비율	21.4%

460 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

7.2%

현재 배당 수익률

-467%

지급 비율

460 신뢰할 수 있는 배당금을 지급하나요?

460 배당 내역 및 벤치마크 참조

예정된 배당금을 받으려면 언제까지 460 을 구매해야 하나요?
Sihuan Pharmaceutical Holdings Group 배당 날짜
전 배당일	Sep 27 2024
배당금 지급일	Oct 10 2024
전 배당금까지의 일수	1 day
배당금 지급일까지의 일수	12 days

460 신뢰할 수 있는 배당금을 지급하나요?

460 배당 내역 및 벤치마크 참조

460 주식 개요

보상

위험 분석

Sihuan Pharmaceutical Holdings Group Ltd. 경쟁사

SEHK:1349

HK$6.4b

SEHK:3613

HK$7.2b

SEHK:1681

HK$5.6b

SEHK:1666

HK$6.6b

가격 내역 및 성능

최근 뉴스 및 업데이트

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Recent updates

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Now 21% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021